

## Lyme disease: diagnosis and management

[K] Evidence review for the management of non-neurological ocular manifestations

*NICE guideline*

*Evidence review*

*September 2017*

*Draft for Consultation*

*This evidence review was developed by  
the National Guideline Centre*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2017. All rights reserved. Subject to Notice of rights.

ISBN:

# Contents

<b>1</b>	<b>Management (non-neurological ocular manifestations)</b> .....	<b>6</b>
1.1	Review question: What is the most clinically and cost-effective treatment for people with non-neurological ocular manifestations related to Lyme disease (for example, keratitis, uveitis, iritis or scleritis)? .....	6
1.2	Introduction .....	6
1.3	PICO table.....	6
1.4	Clinical evidence .....	7
1.4.1	Included studies .....	7
1.4.2	Excluded studies.....	7
1.4.3	Summary of clinical studies included in the evidence review.....	7
1.4.4	Quality assessment of clinical studies included in the evidence review .....	8
1.5	Economic evidence .....	9
1.5.1	Included studies .....	9
1.5.2	Excluded studies.....	9
1.5.3	Unit costs .....	10
1.6	Resource impact .....	13
1.7	Evidence statements .....	13
1.7.1	Clinical evidence statements.....	13
1.7.2	Health economic evidence statements.....	13
1.8	Recommendations .....	13
1.9	Rationale and impact.....	13
1.9.1	Why the committee did not make any recommendations .....	13
1.9.2	Impact of the recommendations on practice.....	13
1.10	The committee’s discussion of the evidence.....	13
1.10.1	Interpreting the evidence.....	13
1.10.2	Cost effectiveness and resource use .....	14
1.10.3	Other factors the committee took into account .....	14
	<b>Appendices</b> .....	<b>28</b>
	Appendix A: Review protocols .....	28
	Appendix B: Literature search strategies .....	33
	B.1 Clinical search literature search strategy .....	33
	B.2 Health Economics literature search strategy.....	35
	Appendix C: Clinical evidence selection.....	41
	Appendix D: Clinical evidence tables .....	42
	Appendix E: Forest plots.....	43
	Appendix F: GRADE tables .....	44
	Appendix G: Health economic evidence selection.....	45
	Appendix H: Health economic evidence tables .....	46

Appendix I: Excluded studies.....	47
I.1 Excluded clinical studies.....	47
I.2 Excluded health economic studies.....	51

# 1 Management (non-neurological ocular manifestations)

## 3 1.1 Review question: What is the most clinically and cost-effective treatment for people with non-neurological ocular manifestations related to Lyme disease (for example, keratitis, uveitis, iritis or scleritis)?

## 7 1.2 Introduction

8 Ocular presentations of Lyme disease are rare and therefore potentially under diagnosed.  
9 The diagnosis is difficult to confirm but serological blood tests and polymerase chain reaction  
10 (PCR) of vitreal fluid may be helpful if possible. Symptoms may occur soon after the infected  
11 tick bite but can also be delayed for many months. There are a variety of presentations  
12 including keratitis, uveitis, iritis, scleritis, neuroretinitis and panophthalmitis.

## 13 1.3 PICO table

14 For full details, see the review protocol in appendix A.

15 **Table 1: PICO characteristics of review question**

<b>Population</b>	Adults (18 years and over), young people (12 to 17 years) and children (under 12 years) with symptoms consistent with non-neurological ocular manifestations related to Lyme disease: <ul style="list-style-type: none"><li>• keratitis</li><li>• uveitis</li><li>• iritis</li><li>• scleritis</li></ul>
<b>Interventions</b>	Antimicrobials, including but not limited to: <ul style="list-style-type: none"><li>• Penicillins<ul style="list-style-type: none"><li>○ Amoxicillin (oral, IV)</li><li>○ Ampicillin (oral, IV)</li><li>○ Benzylpenicillin sodium / Penicillin G (IV)<ul style="list-style-type: none"><li>- Including Augmentin (Amoxicillin and clavulanic acid; oral, IV)</li></ul></li><li>○ Phenoxyethylpenicillin / Penicillin V (oral)</li></ul></li><li>• Tetracyclines<ul style="list-style-type: none"><li>○ Doxycycline (oral)</li><li>○ Minocycline (oral)</li></ul></li><li>• Cephalosporins<ul style="list-style-type: none"><li>○ Cefotaxime (IV)</li><li>○ Ceftriaxone (IV)</li><li>○ Cefuroxime axetil (oral)</li></ul></li><li>• Macrolides<ul style="list-style-type: none"><li>○ Azithromycin (oral)</li><li>○ Clarithromycin (oral, IV)</li></ul></li><li>• Fluoroquinolones<ul style="list-style-type: none"><li>○ Ciprofloxacin (oral, IV)</li><li>○ Levofloxacin (oral, IV)</li><li>○ Moxifloxacin (oral, IV)</li></ul></li></ul>

	<ul style="list-style-type: none"> <li>○ Nalidixic acid (oral)</li> <li>○ Norfloxacin (oral)</li> <li>○ Ofloxacin (oral, IV)</li> <li>● Rifampicin (oral, IV)</li> </ul> <p>Steroids (corticosteroids; oral, IV, topical, intravitreal)</p> <p>Non-steroidal anti-inflammatory drugs (NSAIDs; oral, IV, topical, intravitreal)</p> <p>Mydriatics</p> <ul style="list-style-type: none"> <li>● Acetylcholine (topical)</li> <li>● Phenylephrine (topical)</li> </ul>
<b>Comparisons</b>	<ul style="list-style-type: none"> <li>● Any type of intervention compared to each other           <ul style="list-style-type: none"> <li>○ If data are available consider:               <ul style="list-style-type: none"> <li>- Type of agent (within class or between class)</li> <li>- Route of administration</li> <li>- Duration of treatment: 1 month versus longer</li> </ul> </li> </ul> </li> <li>● Monotherapy versus polytherapy (any combination)</li> <li>● Antimicrobial treatment, steroids, NSAIDs or mydriatics compared to no treatment / placebo</li> </ul>
<b>Outcomes</b>	<p><b>Critical:</b></p> <ol style="list-style-type: none"> <li>1. Quality of life (any validated measure)</li> <li>2. Cure (resolution of non-neurological ocular symptoms)</li> <li>3. Reduction of non-neurological ocular symptoms</li> <li>4. Relapse of non-neurological ocular symptoms</li> </ol> <p><b>Important:</b></p> <ol style="list-style-type: none"> <li>5. Adverse events</li> </ol>
<b>Study design</b>	<ul style="list-style-type: none"> <li>● RCTs</li> <li>● Cohort studies (if no RCT evidence is found)</li> </ul>

## 1 1.4 Clinical evidence

### 2 1.4.1 Included studies

3 No relevant RCTs and cohort studies comparing the effectiveness of antibiotics, steroids,  
 4 NSAIDs or mydriatics versus each other or placebo as treatment for people with non-  
 5 neurological ocular manifestations related to Lyme disease were identified.

6 See also the study selection flow chart in appendix C.

### 7 1.4.2 Excluded studies

8 See the excluded studies list in appendix I.

### 9 1.4.3 Summary of clinical studies included in the evidence review

10 No relevant clinical studies were identified.

1 **1.4.4 Quality assessment of clinical studies included in the evidence review**

2 No relevant clinical studies were identified.



1 **1.5 Economic evidence**

2 **1.5.1 Included studies**

3 No relevant health economic studies were identified.

4 See also the health economic study selection flow chart in appendix G.

5 **1.5.2 Excluded studies**

6 No relevant health economic studies were identified and excluded.

1 **1.5.3 Unit costs**

2 The following unit costs were presented to the committee to aid consideration of cost-effectiveness.

3 **Table 2: UK costs of antimicrobials**

Class	Drug	Age	Preparation	Mg/unit	Cost/unit (£)	Units/day	Course duration (days)	Cost per course (£)
Penicillins	Amoxicillin	7 days-11 months	125 mg/1.25 ml oral suspension paediatric	125	0.20	3	14–28	8.35–16.70
		1-4 years	250 mg/5 ml oral suspension	250	0.06	3	14–28	2.37–4.75
		>5 years	capsules	500	0.06	3	14–28 (g)	2.54–5.08
Penicillins	Phenoxymethylpenicillin	Adults (a)	tablets	250	0.04	4	10	1.49
Tetracyclines	Doxycycline	>12 years	capsules	100	0.11	2	10–28 (h)	2.18–6.09
Cephalosporins	Cefuroxime axetil	>3 months	tablets	250	1.27	4	14–28 (g)	70.88–141.76
Macrolide	Clarithromycin	>1 month	tablets	500	0.16	2	14–21	4.42–6.63
Macrolide	Azithromycin	<12 years	40 mg/1 ml oral suspension	40	0.27	10 mg/kg	9 (i)	Weight dependent
		Adults	tablets	500	0.42	1	9 (i)	3.75
Cephalosporins	Cefotaxime	Adults (b)	2 g powder for solution for injection vials (IV)	2,000	3.75	3	10	112.50
Cephalosporins	Ceftriaxone	>9 years (c)(d)	2 g powder for solution for injection vials (IV) (e)	2,000	1.03	1	14–21	14.42–21.63
Penicillins	Benzylpenicillin sodium	Adults (f)	600 mg powder for solution for injection vials (IM)	600	2.73	2	3	16.38

4 *Abbreviations: IM: intramuscular; IV: intravenously.*

Sources: Unit costs from NHS Electronic Drug Tariff January 2017,<sup>117</sup> except cefotaxime from BNF, January 2017<sup>20</sup> and ceftriaxone from EMIT March 2017;<sup>37</sup> dosage from BNF and BNF for Children January 2017,<sup>20,21</sup> exceptions below:

- (a) Source of dosage from RCT in adults with ECM: Steere 1983,<sup>164</sup> dosage for Lyme disease not available from BNF or BNF for children.
- (b) Source of dosage from RCT in adults with neuroborreliosis: Pfister 1989<sup>129</sup> and Pfister 1991,<sup>130</sup> dosage for Lyme disease not available from BNF or BNF for children.<sup>20,21</sup>
- (c) For disseminated Lyme borreliosis.
- (d) Dose for neonate and child up to 11 years (body weight <50 kg) 50-80 mg/kg once daily for 14-21 days. BNF for children January 2017.<sup>21</sup>
- (e) Administration can vary in adults and children >1 month: IV infusion over 30 mins or IV injection over 5 mins or deep muscular injection (doses over 1 g divided between more than 1 site): 2 g per day for 14-21 days BNF January 2017.<sup>20</sup>
- (f) Source of dosage from RCT in adults with Lyme arthritis: Steere 1985:<sup>163</sup> 1.2 million U injected in each buttock weekly intramuscularly. Duration 3 weeks. Dosage for Lyme disease not available from BNF or BNF for children.<sup>20,21</sup>
- (g) Course duration for early Lyme 14-21 days; 28 days for Lyme arthritis. BNF January 2017.<sup>20</sup>
- (h) Course duration for early Lyme 10-14 days; 28 days for Lyme arthritis. BNF January 2017.<sup>20</sup>
- (i) Course dose and duration for adults: 500 mg once daily for 3 days, for 3 weeks. For children under 12 years: 10 mg/kg once daily for 3 days for 3 weeks. Committee expert opinion.

The cost of intravenous antibiotics will vary depending on where these are administered and by whom. These costs will include some of the following cost components:

- antibiotic
- nursing time (for example, Band 6 nurse, £44 per hour, PSSRU 2016<sup>40</sup>)
- clinic space and clerical time (for outpatient administration)
- travel time (for home administration)
- hospital bed (for inpatient administration)
- consumables (for example, cannula, needles, syringes, dressing, IV giving set and glucose or sodium chloride solution).

A large proportion of the total cost of intravenous antibiotics is likely to be the cost of administration rather than the drug itself. As a result, intravenous drugs that have multiple doses administered per day will be more costly than those administered once daily. This was explored in a detailed costing analysis conducted for the NICE CG102 (Meningitis [bacterial] and meningococcal septicaemia in under 16s).<sup>114</sup> In this analysis, they found that ceftriaxone was the cheapest antibiotic when compared to cefotaxime and benzylpenicillin. This was due to savings in staff time associated with once daily dosing, which offset the higher cost of the drug itself.

### Inpatient administration

Intravenous antibiotics administered in an inpatient setting will incur the cost of an inpatient stay, which is assumed to include intravenous antibiotics treatment as part of the unit cost. The weighted average unit cost of non-elective inpatient stays and day cases for infectious disease in adults and children are summarised estimated in the table below using the NHS reference costs 2015/2016.<sup>45</sup>

**Table 3: Unit costs of inpatient administration**

Schedule	Currency description	Currency codes	Weighted average unit costs (per day)
Day-case adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01B, WJ01D, WJ01E, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£352
Day-case paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£448
Non-elective inpatient short-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£432
Non-elective inpatient short-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£521
Non-elective inpatient long-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£473
Non-elective inpatient long-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£699

Source: NHS reference costs 2015/2016<sup>45</sup>

### Outpatient administration

Intravenous antibiotics may also be administered as part of an outpatient parenteral antibiotic therapy (OPAT) service, which is available in some hospitals. This allows for administration in an outpatient clinic or in a home setting by a district nurse and is for people who require parenteral treatment but are otherwise stable and well enough not to be in hospital. There is currently no NHS reference cost for this service.

A UK study by Chapman 2009<sup>29</sup> reports that this type of service costs between 41% and 61% of the equivalent inpatient costs. Based on these estimates from Chapman 2009 and the unit cost for an adult day case in Table 3, the cost of OPAT would be approximately £144 to £215 per day. These costs would include the cost of the drug as well as the administration.

## 1 **1.6 Resource impact**

2 We do not expect recommendations resulting from this review area to have a significant  
3 impact on resources.

## 4 **1.7 Evidence statements**

### 5 **1.7.1 Clinical evidence statements**

6 No relevant evidence was identified.

### 7 **1.7.2 Health economic evidence statements**

8 No relevant economic evaluations were identified.

## 9 **1.8 Recommendations**

10 No recommendations were made for this review question.

## 11 **1.9 Rationale and impact**

### 12 **1.9.1 Why the committee did not make any recommendations**

13 The guideline committee did not make any recommendations because no evidence for the  
14 management of non-neurological ocular manifestations of Lyme disease was identified. The  
15 committee decided that specialist investigation was likely unless there was clear support  
16 from history and other symptoms that Lyme disease was the likely diagnosis.

### 17 **1.9.2 Impact of the recommendations on practice**

18 No recommendations were made for this review question.

## 19 **1.10 The committee's discussion of the evidence**

### 20 **1.10.1 Interpreting the evidence**

#### 21 **1.10.1.1 The outcomes that matter most**

22 The guideline committee considered quality of life, cure or the resolution of non-neurological  
23 ocular symptoms, the reduction of non-neurological ocular symptoms, and the relapse of  
24 non-neurological ocular symptoms to be critical outcomes. Adverse events as a result of  
25 treatment were considered to be an important outcome.

26 No evidence for any of the outcomes was identified for this review.

#### 27 **1.10.1.2 The quality of the evidence**

28 No evidence was identified for this review.

#### 29 **1.10.1.3 Benefits and harms**

30 No evidence was identified for this review.

1 **1.10.2 Cost effectiveness and resource use**

2 No relevant health economic evidence was identified. The unit costs of different  
3 antimicrobials were presented to the committee.

4 **1.10.3 Other factors the committee took into account**

5 The committee were aware that it is difficult to diagnose Lyme disease as a cause of non-  
6 neurological ocular symptoms.

7 The committee agreed that people with Lyme disease and non-neurological ocular symptoms  
8 would probably also present with other symptoms suggestive of Lyme disease. In these  
9 situations, using the treatment for the other symptoms associated with Lyme disease would  
10 usually be appropriate.

11 The committee considered, however, that investigation and management of people with  
12 more severe ocular symptoms was a matter for specialist practice and that it would be usual  
13 practice for an ophthalmologist to be involved in their care. The committee agreed not to  
14 make specific recommendations in this area because of the lack of evidence and the  
15 specialist nature of treatment. The committee made a general research recommendation for  
16 antibiotic management of Lyme disease but did not prioritise this area for a separate  
17 research recommendation.

## References

1. Aberer E, Kahofer P, Binder B, Kinaciyan T, Schauerl H, Berghold A. Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. *Dermatology*. 2006; 212(2):160-167
2. Abrutyn E. New uses for old drugs. *Infectious Disease Clinics of North America*. 1989; 3(3):653-664
3. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of *Borrelia burgdorferi* to five oral cephalosporins and ceftriaxone. *Antimicrobial Agents and Chemotherapy*. 1992; 36(8):1788-1790
4. Agus B. The recognition and treatment of Lyme disease. *Primary Care Update for Ob/Gyns*. 1995; 2(6):200-203
5. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *Journal of Antimicrobial Chemotherapy*. 2006; 58(2):256-265
6. Ahmed A. When is facial paralysis Bell palsy? current diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2005; 72(5):398-405
7. Ahmed S, Rashid S, Chaudhary A, Bischof E. A patient with Lyme disease: complete heart block treated with antibiotics. *Primary Care Cardiovascular Journal*. 2013; 6(3):117-118
8. Alarcon GS, Mikhail IS. Antimicrobials in the treatment of rheumatoid arthritis and other arthritides: a clinical perspective. *American Journal of the Medical Sciences*. 1994; 308(3):201-209
9. Andiman WA. Lyme disease: epidemiology, etiology, clinical spectrum, diagnosis, and treatment. *Advances in Pediatric Infectious Diseases*. 1986; 1:163-186
10. Anonymous. Antibiotic prophylaxis of Lyme disease following recognized tick bite. Bacterial Zoonoses Branch, Division of Vector-Borne Infectious Diseases National Center for Infectious Diseases, Centers for Disease Control. *Connecticut Medicine*. 1991; 55(12):691-693
11. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. *Infectious Disease Clinics of North America*. 2015; 29(2):269-280
12. Auwaerter PG, Aucott J, Dumler JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. *Expert Reviews in Molecular Medicine*. 2004; 6(2):1-22
13. Bennet L, Danell S, Berglund J. Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. *Scandinavian Journal of Infectious Diseases*. 2003; 35(2):129-131
14. Berende A, ter Hofstede HJ, Donders AR, van Middendorp H, Kessels RP, Adang EM et al. Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. *BMC Infectious Diseases*. 2014; 14:543
15. Berger BW. Treating erythema chronicum migrans of Lyme disease. *Journal of the American Academy of Dermatology*. 1986; 15(3):459-463

- 1 16. Berger BW. Treatment of erythema chronicum migrans of Lyme disease. *Annals of*  
2 *the New York Academy of Sciences*. 1988; 539:346-351
- 3 17. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline  
4 inhibit the inflammatory responses to the Lyme disease spirochete *Borrelia*  
5 *burgdorferi*. *Journal of Infectious Diseases*. 2009; 199(9):1379-1388
- 6 18. Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. *Journal*  
7 *of the American Academy of Dermatology*. 2011; 64(4):639-653
- 8 19. Bjark PH. Re: No prolonged antibiotic therapy for disease attributed to borreliosis.  
9 *Tidsskrift for den Norske Laegeforening*. 2016; 136(20):1702-1703
- 10 20. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National  
11 Formulary. Available from: <https://www.evidence.nhs.uk/formulary/bnf/current> Last  
12 accessed: 04 April 2017.
- 13 21. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National  
14 Formulary for Children. Available from:  
15 <https://www.evidence.nhs.uk/formulary/bnf/current> Last accessed: 04 April 2017.
- 16 22. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J et al.  
17 Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme  
18 neuroborreliosis. *Scandinavian Journal of Infectious Diseases*. 2005; 37(6-7):449-454
- 19 23. Bratton RL, Whiteside JW, Hovan MJ, Engle RL, Edwards FD. Diagnosis and  
20 treatment of lyme disease. *Mayo Clinic Proceedings*. 2008; 83(5):566-571
- 21 24. Bremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of  
22 encephalitis, myelitis, vasculitis or intracranial hypertension. *European Journal of*  
23 *Neurology*. 2014; 21(9):1162-1167
- 24 25. British Infection Association. The epidemiology, prevention, investigation and  
25 treatment of Lyme borreliosis in United Kingdom patients: A position statement by the  
26 British Infection Association. *Journal of Infection*. 2011; 62(5):329-338
- 27 26. Butler T, Jones PK, Wallace CK. *Borrelia recurrentis* infection: single-dose antibiotic  
28 regimens and management of the Jarisch-Herxheimer reaction. *Journal of Infectious*  
29 *Diseases*. 1978; 137(5):573-577
- 30 27. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the  
31 neurological complications of Lyme disease. *Cochrane Database of Systematic*  
32 *Reviews* 2016, Issue 12. Art. No.: CD006978. DOI:  
33 10.1002/14651858.CD006978.pub2.
- 34 28. Canadian Paediatric Society. How to diagnose and treat Lyme disease in children.  
35 *Infectious Diseases and Immunization Committee, Canadian Paediatric Society*.  
36 *CMAJ*. 1992; 147(2):169-178
- 37 29. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy  
38 and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK  
39 perspective. *Journal of Antimicrobial Chemotherapy*. 2009; 64(6):1316-1324
- 40 30. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of  
41 antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant  
42 epitopes of outer surface protein a of *Borrelia burgdorferi*. *Arthritis and Rheumatism*.  
43 1999; 42(9):1813-1822
- 44 31. Choo-Kang C, Tang E, Mattappallil A. The treatment of early lyme disease. *US*  
45 *Pharmacist*. 2010; 35(9):41-48



- 1 32. Christian CL. Management of asymptomatic *Borrelia burgdorferi* infection. *Arthritis*  
2 and *Rheumatism*. 1992; 35(11):1395
- 3 33. Cimmino MA. Recognition and management of bacterial arthritis. *Drugs*. 1997;  
4 54(1):50-60
- 5 34. Cimmino MA, Accardo S. Long term treatment of chronic Lyme arthritis with  
6 benzathine penicillin. *Annals of the Rheumatic Diseases*. 1992; 51(8):1007-1008
- 7 35. Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Strle F. Lyme meningitis:  
8 a one-year follow up controlled study. *Wiener Klinische Wochenschrift*. 1999; 111(22-  
9 23):961-963
- 10 36. Coblyn JS, Taylor P. Treatment of chronic Lyme arthritis with hydroxychloroquine.  
11 *Arthritis and Rheumatism*. 1981; 24(12):1567-1569
- 12 37. Commercial Medicines Unit (CMU), Department of Health. Electronic market  
13 information tool (EMIT). 2011. Available from: [http://cmu.dh.gov.uk/electronic-market-](http://cmu.dh.gov.uk/electronic-market-information-tool-emit/)  
14 [information-tool-emit/](http://cmu.dh.gov.uk/electronic-market-information-tool-emit/) Last accessed: 4 April 2017.
- 15 38. Committee on Infectious Diseases. Erratum: Treatment of lyme borreliosis (*Pediatrics*  
16 (July 1991) 88 (7-19)). *Pediatrics*. 1991; 88(4):840
- 17 39. Cuisset T, Hamilos M, Vanderheyden M. Coronary aneurysm in Lyme disease:  
18 treatment by covered stent. *International Journal of Cardiology*. 2008; 128(2):e72-e73
- 19 40. Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury. Personal  
20 Social Services Research Unit University of Kent, 2016. Available from:  
21 <http://www.pssru.ac.uk/project-pages/unit-costs/2016/>
- 22 41. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme  
23 disease: a pilot study. *Antimicrobial Agents and Chemotherapy*. 1996; 40(2):468-469
- 24 42. Dattwyler RJ, Halperin JJ. Failure of tetracycline therapy in early Lyme disease.  
25 *Arthritis and Rheumatism*. 1987; 30(4):448-450
- 26 43. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis -  
27 randomised comparison of ceftriaxone and penicillin. *Lancet*. 1988; 1(8596):1191-  
28 1194
- 29 44. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E et al. A  
30 comparison of two treatment regimens of ceftriaxone in late Lyme disease. *Wiener*  
31 *Klinische Wochenschrift*. 2005; 117(11-12):393-397
- 32 45. Department of Health. NHS reference costs 2015-16. 2016. Available from:  
33 [https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-](https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016)  
34 [for-2015-to-2016](https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016) Last accessed: 4 April 2017.
- 35 46. Dersch R, Freitag MH, Schmidt S, Sommer H, Rauer S, Meerpohl JJ. Efficacy and  
36 safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic  
37 review. *European Journal of Neurology*. 2015; 22(9):1249-1259
- 38 47. Dersch R, Freitag MH, Schmidt S, Sommer H, Rucker G, Rauer S et al. Efficacy and  
39 safety of pharmacological treatments for neuroborreliosis--protocol for a systematic  
40 review. *Systems Review*. 2014; 3:117
- 41 48. Dersch R, Rauer S. Treatment and long-term outcome of Lyme neuroborreliosis.  
42 *Aktuelle neurologie*. 2017; 43(10):608-614

- 1 49. Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual  
2 symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic  
3 review. *Journal of Neurology*. 2016; 263(1):17-24
- 4 50. Dhoot DS, Martin DF, Srivastava SK. Pediatric infectious posterior uveitis.  
5 *International Ophthalmology Clinics*. 2011; 51(1):113-128
- 6 51. Dinser R, Jendro MC, Schnarr S, Zeidler H. Antibiotic treatment of Lyme borreliosis:  
7 what is the evidence? *Annals of the Rheumatic Diseases*. 2005; 64(4):519-523
- 8 52. Dotevall L, Alestig K, Hanner P, Norkrans G, Hagberg L. The use of doxycycline in  
9 nervous system *Borrelia burgdorferi* infection. *Scandinavian Journal of Infectious  
10 Diseases Supplement*. 1988; 53:74-79
- 11 53. Eliassen KE, Berild D, Reiso H, Grude N, Christophersen KS, Finckenhagen C et al.  
12 Incidence and antibiotic treatment of erythema migrans in Norway 2005-2009. *Ticks  
13 and Tick-Borne Diseases*. 2017; 8(1):1-8
- 14 54. Eliassen KE, Hjetland R, Reiso H, Lindbaek M, Tschudi-Madsen H. Symptom load  
15 and general function among patients with erythema migrans: a prospective study with  
16 a 1-year follow-up after antibiotic treatment in Norwegian general practice.  
17 *Scandinavian Journal of Primary Health Care*. 2017; 35(1):75-83
- 18 55. Eppes SC. Diagnosis, treatment, and prevention of Lyme disease in children.  
19 *Pediatric Drugs*. 2003; 5(6):363-372
- 20 56. Esposito S, Baggi E, Villani A, Norbedo S, Pellegrini G, Bozzola E et al. Management  
21 of paediatric Lyme disease in non-endemic and endemic areas: data from the registry  
22 of the Italian Society for Pediatric Infectious Diseases. *European Journal of Clinical  
23 Microbiology and Infectious Diseases*. 2013; 32(4):523-529
- 24 57. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E et al. A  
25 randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme  
26 encephalopathy. *Neurology*. 2008; 70(13):992-1003
- 27 58. Fallon BA, Tager F, Fein L, Liegner K, Keilp J, Weiss N et al. Repeated antibiotic  
28 treatment in chronic Lyme disease. *Journal of Spirochetal and Tick-borne Diseases*.  
29 1999; 6(4):94-102
- 30 59. Galev A, Zvetkov V, Genov K. Pulse therapy with ceftriaxone on Lyme  
31 neuroborreliosis. *Problems of Infectious and Parasitic Diseases*. 2005; 33(1):15-17
- 32 60. Garkowski A, Zajkowska J, Zajkowska A, Kulakowska A, Zajkowska O, Kubas B et al.  
33 Cerebrovascular manifestations of Lyme neuroborreliosis-a systematic review of  
34 published cases. *Frontiers in Neurology*. 2017; 8:146
- 35 61. Gasser R, Reisinger E, Eber B, Pokan R, Seinost G, Bergloff J et al. Cases of Lyme  
36 borreliosis resistant to conventional treatment: improved symptoms with  
37 cephalosporin plus specific beta-lactamase inhibition. *Microbial Drug Resistance*.  
38 1995; 1(4):341-344
- 39 62. Gasser R, Reisinger E, Sedaj B, Horvarth R, Seinost G, Keplinger A et al. Oral  
40 treatment of late Lyme borreliosis with a combination of roxithromycin and co-  
41 trimoxazole--a pilot study on 18 patients. *Acta Medica Austriaca*. 1996; 23(3):99-101
- 42 63. Gasser R, Wendelin I, Reisinger E, Bergloff J, Feigl B, Schafhalter I et al.  
43 Roxithromycin in the treatment of Lyme disease--update and perspectives. *Infection*.  
44 1995; 23 (Suppl.1):S39-43

- 1 64. Gerber MA, Shapiro ED, Burke GS, Parcels VJ, Bell GL. Lyme disease in children in  
2 southeastern Connecticut. *Pediatric Lyme Disease Study Group. New England*  
3 *Journal of Medicine*. 1996; 335(17):1270-1274
- 4 65. Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P et al.  
5 Common harms from amoxicillin: a systematic review and meta-analysis of  
6 randomized placebo-controlled trials for any indication. *CMAJ*. 2015; 187(1):E21-E31
- 7 66. Goodwin SD, Sproat TT, Russell WL. Management of Lyme disease. *Clinical*  
8 *Pharmacy*. 1990; 9(3):192-205
- 9 67. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sørensen L et al.  
10 Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal  
11 susceptibility study and a clinical trial in patients with erythema migrans. *Acta*  
12 *Dermato-Venereologica*. 1992; 72(4):297-300
- 13 68. Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime  
14 versus penicillin in the late stage of Lyme disease: prospective, randomized  
15 therapeutic study. *Infection*. 1990; 18(1):16-20
- 16 69. Horton DB, Taxter AJ, Groh B, Sherry DD, Rose CD. Clinical and treatment factors  
17 associated with antibiotic-refractory Lyme arthritis in children. *Arthritis and*  
18 *Rheumatology*. 2017; 68(S10):3140-3143
- 19 70. Hu LT, Klempner MS. Update on the prevention, diagnosis, and treatment of Lyme  
20 disease. *Advances in Internal Medicine*. 2001; 46:247-275
- 21 71. Inboriboon PC. Early recognition and management of Lyme carditis. *International*  
22 *Journal of Emergency Medicine*. 2010; 3(4):489-490
- 23 72. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT et al. Cognitive  
24 function in post-treatment Lyme disease: do additional antibiotics help? *Neurology*.  
25 2003; 60(12):1916-1922
- 26 73. Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral  
27 doxycycline for Lyme neuroborreliosis. *Scandinavian Journal of Infectious Diseases*.  
28 2001; 33(4):259-262
- 29 74. Karlsson M, Hammers S, Nilsson-Ehle I, Malmberg AS, Wretling B. Concentrations of  
30 doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for  
31 neuroborreliosis. *Antimicrobial Agents and Chemotherapy*. 1996; 40(5):1104-1107
- 32 75. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and  
33 doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrobial Agents and*  
34 *Chemotherapy*. 1995; 39(5):1127-1133
- 35 76. Kilic Muftuoglu I, Aydin Akova Y, Gur Gungor S. A case of Lyme disease  
36 accompanied by uveitis and white dot syndrome. *Turkish Journal of Ophthalmology*.  
37 2016; 46(5):241-243
- 38 77. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment  
39 chronic Lyme disease. *Vector Borne and Zoonotic Diseases*. 2002; 2(4):255-263
- 40 78. Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ et al.  
41 Treatment trials for post-lyme disease symptoms revisited. *American Journal of*  
42 *Medicine*. 2013; 126(8):665-669
- 43 79. Korenberg EI, Vorobyeva NN, Moskvitina HG, Gorban Ln. Prevention of borreliosis in  
44 persons bitten by infected ticks. *Infection*. 1996; 24(2):187-189

- 1 80. Kowalski TJ, Berth WL, Mathiason MA, Agger WA. Oral antibiotic treatment and long-  
2 term outcomes of Lyme facial nerve palsy. *Infection*. 2011; 39(3):239-245
- 3 81. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment  
4 duration and long-term outcomes of patients with early Lyme disease from a Lyme  
5 disease-hyperendemic area. *Clinical Infectious Diseases*. 2010; 50(4):512-520
- 6 82. Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. *Infection*. 1996;  
7 24(2):170-173
- 8 83. Kuhn M, Grave S, Bransfield R, Harris S. Long term antibiotic therapy may be an  
9 effective treatment for children co-morbid with Lyme disease and autism spectrum  
10 disorder. *Medical Hypotheses*. 2012; 78(5):606-615
- 11 84. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term  
12 prognosis of reactive arthritis. *Annals of the Rheumatic Diseases*. 2003; 62(7):655-  
13 658
- 14 85. Lantos PM, Brinkerhoff RJ, Wormser GP, Clemen R. Empiric antibiotic treatment of  
15 erythema migrans-like skin lesions as a function of geography: a clinical and cost  
16 effectiveness modeling study. *Vector Borne and Zoonotic Diseases*. 2013;  
17 13(12):877-883
- 18 86. Lauhio A, Konttinen YT, Salo T, Tschesche H, Lahdevirta J, Woessner FJ et al.  
19 Placebo-controlled study of the effects of three-month lymecyclille treatment on  
20 serum matrix metalloproteinases in reactive arthritis. *Annals of the New York  
21 Academy of Sciences*. 1994; 732:424-426
- 22 87. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-  
23 controlled study of three-month treatment with lymecycline in reactive arthritis, with  
24 special reference to Chlamydia arthritis. *Arthritis and Rheumatism*. 1991; 34(1):6-14
- 25 88. Liegner KB. Minocycline in Lyme disease. *Journal of the American Academy of  
26 Dermatology*. 1992; 26(2 Pt 1):263-264
- 27 89. Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B. Long-term prognosis of patients  
28 treated for erythema migrans in France. *British Journal of Dermatology*. 2002;  
29 146(5):872-876
- 30 90. Ljostad U, Eikeland R, Midgard R, Skogvoll E, Skarpass T, Berg A. Oral doxycycline  
31 vs. IV centriaxone for European Lyme neuro-borreliosis. A double-blind, randomized  
32 controlled clinical trial. *European Journal of Neurology*. 2008; 15(Suppl 3):338-389
- 33 91. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme  
34 disease *Drugs*. 1999; 57(2):157-173
- 35 92. Loewen PS, Marra CA, Marra F. Erratum: Systemic review of the treatment of early  
36 Lyme disease (*Drugs* (1999) 57 (2) (157-173)). *Drugs*. 2000; 59(3):476
- 37 93. Luft BJ, Halperin JJ, Volkman DJ, Dattwyler RJ. Ceftriaxone -an effective treatment of  
38 late Lyme borreliosis. *Journal of Chemotherapy*. 1989; 1(Suppl 4):917-919
- 39 94. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches  
40 in the treatment of Lyme borreliosis. *Annals of the New York Academy of Sciences*.  
41 1988; 539:352-361
- 42 95. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Treatment of  
43 erythema migrans in pregnancy. *Clinical Infectious Diseases*. 1996; 22(5):788-793
- 44 96. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Erythema  
45 migrans in pregnancy. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):933-940

- 1 97. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T, Picken RN et al.  
2 Solitary borrelial lymphocytoma in adult patients. *Wiener Klinische Wochenschrift*.  
3 2002; 114(13-14):515-523
- 4 98. Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljić E, Strle F. Erythema  
5 migrans in the immunocompromised host. *Wiener Klinische Wochenschrift*. 1999;  
6 111(22-23):923-932
- 7 99. Maraspin V, Lotric-Furlan S, Strle F. Development of erythema migrans in spite of  
8 treatment with antibiotics after a tick bite. *Wiener Klinische Wochenschrift*. 2002;  
9 114(13-14):616-619
- 10 100. Maraspin V, Ruzic-Sabljić E, Strle F, Cimperman J, Jereb M, Preac-Mursic V.  
11 Persistence of *Borrelia burgdorferi* after treatment with antibiotics. *Alpe Adria*  
12 *Microbiology Journal*. 1995; 4(3):211-216
- 13 101. Marks CM, Nawn JE, Caplow JA. Antibiotic treatment for chronic Lyme disease -say  
14 no to the DRESS. *JAMA Internal Medicine*. 2016; 176(12):1745-1746
- 15 102. McGill IG, Bienenstock J. A comparative clinical trial of lymecycline. *British Journal of*  
16 *Clinical Practice*. 1965; 19:462-464
- 17 103. Meyerhoff J. Prolonged antibiotic treatment did not relieve chronic symptoms in Lyme  
18 disease. *ACP Journal Club*. 2002; 136(2):57
- 19 104. Meyerhoff J. Long-term antibiotics after ceftriaxone did not improve quality of life in  
20 persistent Lyme disease. *Annals of Internal Medicine*. 2016; 165(2):JC5
- 21 105. Millner MM, Thalhammer GH. Neuroborreliosis in childhood: treatment with penicillin  
22 sodium and ceftriaxone. *Acta Dermatovenerologica Alpina, Panonica et Adriatica*.  
23 1996; 5(3-4):169-172
- 24 106. Millner MM, Thalhammer GH, Dittrich P, Spork KD, Brunner M, Georgopoulos A.  
25 Beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary  
26 results. *Infection*. 1996; 24(2):174-177
- 27 107. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children.  
28 *Journal of Pediatric Ophthalmology and Strabismus*. 2000; 37(5):254-259
- 29 108. Muellegger R, Zöchling N, Schluëpen EM, Soyer HP, Hoedl S, Kerl et al.  
30 Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis.  
31 *Infection*. 1996; 24(1):76-79
- 32 109. Muellegger RR, Zöchling N, Soyer HP, Hoedl S, Wienecke R, Volkenandt M et al.  
33 No detection of *Borrelia burgdorferi*-specific DNA in erythema migrans lesions after  
34 minocycline treatment. *Archives of Dermatology*. 1995; 131(6):678-682
- 35 110. Müllegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone  
36 in the treatment of neuroborreliosis in children--a prospective study. *Infection*. 1991;  
37 19(4):279-283
- 38 111. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D et al.  
39 Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an  
40 *Ixodes scapularis* tick bite. *New England Journal of Medicine*. 2001; 345(2):79-84
- 41 112. Nadelman RB, Nowakowski J, Forseter G, Bittker S, Cooper D, Goldberg N et al.  
42 Failure to isolate *Borrelia burgdorferi* after antimicrobial therapy in culture-  
43 documented Lyme borreliosis associated with erythema migrans: report of a  
44 prospective study. *American Journal of Medicine*. 1993; 94(6):583-588

- 1 113. Naglo AS, Wide K. Borrelia infection in children. *Acta Paediatrica Scandinavica*.  
2 1989; 78(6):918-922
- 3 114. National Collaborating Centre for Women's and Children's Health. Meningitis  
4 (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and  
5 management. NICE clinical guideline 102. London. RCOG Press, 2010. Available  
6 from: <http://guidance.nice.org.uk/CG102>
- 7 115. National Institute for Health and Care Excellence. Developing NICE guidelines: the  
8 manual. London. National Institute for Health and Care Excellence, 2014. Available  
9 from:  
10 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 11 116. Neumann R, Aberer E, Stanek G. Treatment and course of erythema chronicum  
12 migrans. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical*  
13 *Microbiology, Infectious Diseases, Virology, Parasitology*. 1987; 263(3):372-376
- 14 117. NHS Business Services Authority. NHS electronic drug tariff March 2017. Available  
15 from: [http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC\\_2/DC00446511/Home](http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC_2/DC00446511/Home) Last  
16 accessed: 4 April 2017.
- 17 118. Nimmrich S, Becker I, Horneff G. Intraarticular corticosteroids in refractory childhood  
18 Lyme arthritis. *Rheumatology International*. 2014; 34(7):987-994
- 19 119. Nowakowski J, McKenna D, Nadelman RB, Cooper D, Bittker S, Holmgren D et al.  
20 Failure of treatment with cephalexin for Lyme disease. *Archives of Family Medicine*.  
21 2000; 9(6):563-567
- 22 120. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline  
23 versus tetracycline therapy for Lyme disease associated with erythema migrans.  
24 *Journal of the American Academy of Dermatology*. 1995; 32(2 Pt 1):223-227
- 25 121. Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzic-Sabljić E, Strle F. Doxycycline  
26 versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. *Wiener*  
27 *Klinische Wochenschrift*. 2006; 118(21):696-701
- 28 122. Oksi J, Marjamäki M, Nikoskelainen J, Viljanen MK. *Borrelia burgdorferi* detected by  
29 culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Annals of*  
30 *Medicine*. 1999; 31(3):225-232
- 31 123. Oksi J, Nikoskelainen J, Hiekkänen H, Lauhio A, Peltomaa M, Pitkäranta A et al.  
32 Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind,  
33 randomized, placebo-controlled, multicenter clinical study. *European Journal of*  
34 *Clinical Microbiology and Infectious Diseases*. 2007; 26(8):571-581
- 35 124. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous  
36 ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. *European*  
37 *Journal of Clinical Microbiology and Infectious Diseases*. 1998; 17(10):715-719
- 38 125. Peltomaa M, Saxen H, Seppälä I, Viljanen M, Pyykkö I. Paediatric facial paralysis  
39 caused by Lyme borreliosis: a prospective and retrospective analysis. *Scandinavian*  
40 *Journal of Infectious Diseases*. 1998; 30(3):269-275
- 41 126. Pena CA, Mathews AA, Siddiqi NH, Strickland GT. Antibiotic therapy for Lyme disease  
42 in a population-based cohort. *Clinical Infectious Diseases*. 1999; 29(3):694-695
- 43 127. Perronne C. Critical review of studies trying to evaluate the treatment of chronic Lyme  
44 disease. *Presse Medicale*. 2015; 44(7-8):828-831

- 1 128. Pfister HW, Einhaupl KM, Franz P, Garner C. Corticosteroids for radicular pain in  
2 Bannwarth's syndrome: a double-blind, randomized, placebo-controlled trial. *Annals*  
3 *of the New York Academy of Sciences*. 1988; 539(1):485-487
- 4 129. Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for  
5 acute neurologic manifestations in Lyme borreliosis. A prospective randomized study.  
6 *Archives of Neurology*. 1989; 46(11):1190-1194
- 7 130. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM.  
8 Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.  
9 *Journal of Infectious Diseases*. 1991; 163(2):311-318
- 10 131. Pirila V. The penicillin treatment of acrodermatitis atrophicans chronica. *Acta*  
11 *Dermato-Venereologica*. 1951; 31(5):576-591
- 12 132. Plorer A, Sepp N, Schmutzhard E, Krabichler S, Trobos S, Schauer G et al. Effects of  
13 adequate versus inadequate treatment of cutaneous manifestations of Lyme  
14 borreliosis on the incidence of late complications and late serologic status. *Journal of*  
15 *Investigative Dermatology*. 1993; 100(2):103-109
- 16 133. Plotkin SA, Peter G. Treatment of Lyme borreliosis. *Pediatrics*. 1991; 88(1):176-179
- 17 134. Puchalska B, Niemcunowicz-Janica A, Kondej Muszynska K, Trippner M. Lyme  
18 borreliosis--tick borne spirochaetosis among children. *Roczniki Akademii Medycznej*  
19 *w Bialymstoku (1995)*. 1996; 41(1):59-61
- 20 135. Puri BK, Hakkarainen-Smith JS, Derham A, Monro JA. Co-administration of alpha-  
21 lipoic acid and glutathione is associated with no significant changes in serum bilirubin,  
22 alkaline phosphatase or gamma-glutamyltranspeptidase levels during the treatment  
23 of neuroborreliosis with intravenous ceftriaxone. *Journal of Complementary and*  
24 *Integrative Medicine*. 2015; 12(3):227-230
- 25 136. Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to  
26 reduce the risk of developing *Clostridium difficile*-associated diarrhoea in patients  
27 receiving long-term intravenous ceftriaxone. *Medical Hypotheses*. 2015; 84(1):78-80
- 28 137. Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN. Characteristics of seroconversion  
29 and implications for diagnosis of post-treatment Lyme disease syndrome: acute and  
30 convalescent serology among a prospective cohort of early Lyme disease patients.  
31 *Clinical Rheumatology*. 2015; 34(3):585-589
- 32 138. Renaud I, Cachin C, Gerster JC. Good outcomes of Lyme arthritis in 24 patients in an  
33 endemic area of Switzerland. *Joint, Bone, Spine: Revue du Rhumatisme*. 2004;  
34 71(1):39-43
- 35 139. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of  
36 Lyme neuroborreliosis. *Infection*. 1996; 24(1):88-90
- 37 140. Rose CD, Fawcett PT, Eppes SC, Klein JD, Gibney K, Doughty RA. Pediatric Lyme  
38 arthritis: clinical spectrum and outcome. *Journal of Pediatric Orthopaedics*. 1994;  
39 14(2):238-241
- 40 141. Rose CD, Fawcett PT, Gibney KM, Doughty RA. Residual serologic reactivity in  
41 children with resolved Lyme arthritis. *Journal of Rheumatology*. 1996; 23(2):367-369
- 42 142. Rubin DA, Sorbera C, Nikitin P, McAllister A, Wormser GP, Nadelman RB.  
43 Prospective evaluation of heart block complicating early Lyme disease. *PACE -*  
44 *Pacing and Clinical Electrophysiology*. 1992; 15(3):252-255

- 1 143. Salazar CA, Rothemich M, Drouin EE, Glickstein L, Steere AC. Human Lyme arthritis  
2 and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related  
3 protein of *Borrelia burgdorferi*. *Infection and Immunity*. 2005; 73(5):2951-2957
- 4 144. Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children  
5 given early treatment. *Journal of Pediatrics*. 1993; 122(4):591-593
- 6 145. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of  
7 Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. *JAMA*.  
8 2016; 315(16):1767-1777
- 9 146. Sandstrom M, Bredberg G, Asbrink E, Hovmark A, Holmkvist C. Brainstem response  
10 audiometry in chronic Lyme borreliosis. *Scandinavian Audiology*. 1989; 18(4):205-210
- 11 147. Schmidt BL, Aberer E, Stockenhuber C, Klade H, Breier F, Luger A. Detection of  
12 *Borrelia burgdorferi* DNA by polymerase chain reaction in the urine and breast milk of  
13 patients with Lyme borreliosis. *Diagnostic Microbiology and Infectious Disease*. 1995;  
14 21(3):121-128
- 15 148. Selby G, Bridges SJ, Hanington L. Should Lyme disease affecting the nervous  
16 system be treated with oral or intravenous antibiotics? *Archives of Disease in  
17 Childhood Education & Practice*. 2008; 93(4):132-134
- 18 149. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP et al. The  
19 long-term clinical outcomes of Lyme disease. A population-based retrospective cohort  
20 study. *Annals of Internal Medicine*. 1994; 121(8):560-567
- 21 150. Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, Wright EA et al.  
22 Musculoskeletal and neurologic outcomes in patients with previously treated Lyme  
23 disease. *Annals of Internal Medicine*. 1999; 131(12):919-926
- 24 151. Shemenski J. Cimetidine as a novel adjunctive treatment for early stage Lyme  
25 disease. *Medical Hypotheses*. 2016; Epublication
- 26 152. Shoemaker RC, Hudnell HK, House DE, Kempen A, Pakes GE. Atovaquone plus  
27 cholestyramine in patients coinfecting with *Babesia microti* and *Borrelia burgdorferi*  
28 refractory to other treatment. *Advances in Therapy*. 2006; 23(1):1-11
- 29 153. Sjowall J, Fryland L, Nordberg M, Sjogren F, Garpmo U, Jansson C et al. Decreased  
30 Th1-type inflammatory cytokine expression in the skin is associated with persisting  
31 symptoms after treatment of erythema migrans. *PLoS One*. 2011; 6(3):e18220
- 32 154. Sjöwall J, Ledel A, Ernerudh J, Ekerfelt C, Forsberg P. Doxycycline-mediated effects  
33 on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a  
34 randomized, prospective, cross-over study. *BMC Infectious Diseases*. 2012; 12:186
- 35 155. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme  
36 neuroborreliosis in children: a prospective study of clinical features, prognosis, and  
37 outcome. *Pediatric Infectious Disease Journal*. 2008; 27(12):1089-1094
- 38 156. Skogman BH, Croner S, Odkvist L. Acute facial palsy in children - a 2-year follow-up  
39 study with focus on Lyme neuroborreliosis. *International Journal of Pediatric  
40 Otorhinolaryngology*. 2003; 67(6):597-602
- 41 157. Skoldenberg B, Stiernstedt G, Karlsson M, Wretling B, Svenungsson B. Treatment of  
42 Lyme borreliosis with emphasis on neurological disease. *Annals of the New York  
43 Academy of Sciences*. 1988; 539:317-323
- 44 158. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL et al.  
45 Clinical characteristics and treatment outcome of early Lyme disease in patients with



- 1 microbiologically confirmed erythema migrans. *Annals of Internal Medicine*. 2002;  
2 136(6):421-428
- 3 159. Solomon SP, Hilton E, Weinschel BS, Pollack S, Grolnick E. Psychological factors in  
4 the prediction of Lyme disease course. *Arthritis Care and Research*. 1998; 11(5):419-  
5 426
- 6 160. Spathling S, J dK, P H. Therapy of Lyme arthritis with ceftriaxon - histological proof of  
7 spirochetes in the synovialis after ineffective therapy. *Zeitschrift für Rheumatologie*.  
8 1992; 51(Suppl 2):40-41
- 9 161. Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H. Erythema migrans  
10 and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia  
11 species. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):951-956
- 12 162. Steere AC, Green J, Hutchinson GJ, Rahn DW, Pachner AR, Schoen RT et al.  
13 Treatment of Lyme disease. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene*  
14 - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology. 1987;  
15 263(3):352-356
- 16 163. Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW et al.  
17 Successful parenteral penicillin therapy of established Lyme arthritis. *New England*  
18 *Journal of Medicine*. 1985; 312(14):869-874
- 19 164. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET et al.  
20 Treatment of the early manifestations of Lyme disease. *Annals of Internal Medicine*.  
21 1983; 99(1):22-26
- 22 165. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic  
23 therapy in Lyme disease. *Annals of Internal Medicine*. 1980; 93(1 I):1-8
- 24 166. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease:  
25 successful treatment with high-dose intravenous penicillin. *Annals of Internal*  
26 *Medicine*. 1983; 99(6):767-772
- 27 167. Steurer J. Month-long antibiotic therapy has no effect in persistent symptoms of Lyme  
28 disease. *Praxis*. 2016; 105(12):723-724
- 29 168. Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L. Benefit of  
30 intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme  
31 disease. *International Journal of General Medicine*. 2011; 4:639-646
- 32 169. Stricker RB, Green CL, Savely VR, Chamallas SN, Johnson L. Safety of intravenous  
33 antibiotic therapy in patients referred for treatment of neurologic Lyme disease.  
34 *Minerva Medica*. 2010; 101(1):1-7
- 35 170. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Cimperman J. Azithromycin and  
36 doxycycline for treatment of borrelia culture-positive erythema migrans. *Infection*.  
37 1996; 24(1):64-68
- 38 171. Strle F, Maraspin V, Pleterski-Rigler D, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T et al.  
39 Treatment of borrelial lymphocytoma. *Infection*. 1996; 24(1):80-84
- 40 172. Strle F, Pleterski-Rigler D, Stanek G, Pejovnik-Pustinek A, Ruzic E, Cimperman J.  
41 Solitary borrelial lymphocytoma: report of 36 cases. *Infection*. 1992; 20(4):201-206
- 42 173. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin  
43 versus doxycycline for treatment of erythema migrans: clinical and microbiological  
44 findings. *Infection*. 1993; 21(2):83-88

- 1 174. Stupica D, Lusa L, Cerar T, Ruzic-Sabljić E, Strle F. Comparison of post-lyme  
2 borreliosis symptoms in erythema migrans patients with positive and negative borrelia  
3 burgdorferi sensu lato skin culture. *Vector-Borne and Zoonotic Diseases*. 2011;  
4 11(7):883-889
- 5 175. Stupica D, Lusa L, Maraspin V, Bogovic P, Vidmar D, O'Rourke M et al. Correlation of  
6 culture positivity, PCR positivity, and burden of *Borrelia burgdorferi sensu lato* in skin  
7 samples of erythema migrans patients with clinical findings. *PLoS One*. 2015;  
8 10(9):e0136600
- 9 176. Suarez-Magdalena O, Fernandez-Jorge B, Campo-Cerecedo F, Varela-Veiga A.  
10 Atrophoderma of Pasini and Pierini associated with *Borrelia burgdorferi* treated with  
11 doxycycline. *Piel*. 2017; 32(2):120-122
- 12 177. Thompson AD, Cohn KA, Shah SS, Lyons T, Welsh EJ, Hines EM et al. Treatment  
13 complications in children with Lyme meningitis. *Pediatric Infectious Disease Journal*.  
14 2012; 31(10):1032-1035
- 15 178. Thorstrand C, Belfrage E, Bennet R, Malmborg P, Eriksson M. Successful treatment  
16 of neuroborreliosis with ten day regimens. *Pediatric Infectious Disease Journal*. 2002;  
17 21(12):1142-1145
- 18 179. Thyresson N. The penicillin treatment of acrodermatitis atrophicans chronica  
19 (Herxheimer). *Acta Dermato-Venereologica*. 1949; 29(6):572-621
- 20 180. Torbahn G, Hofmann H, Allert R, Freitag MH, Dersch R, Fingerle V et al. Efficacy and  
21 safety of pharmacological agents in the treatment of erythema migrans in early Lyme  
22 borreliosis-systematic review protocol. *Systems Review*. 2016; 5:73
- 23 181. Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis:  
24 results of a large pediatric cohort. *Journal of Rheumatology*. 2010; 37(5):1049-1055
- 25 182. Tseng YJ, Demaria A, Goldmann DA, Mandl KD. Claims-based diagnostic patterns of  
26 patients evaluated for lyme disease and given extended antibiotic therapy. *Vector-*  
27 *Borne and Zoonotic Diseases*. 2017; 17(2):116-122
- 28 183. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. Long-term results in  
29 patients with Lyme arthritis following treatment with ceftriaxone. *Infection*. 1996;  
30 24(1):98-102
- 31 184. Vazquez-Lopez ME, Diez-Morrondo C, Sanchez-Andrade A, Pego-Reigosa R, Diaz  
32 P, Castro-Gago M. Articular manifestations in patients with Lyme disease.  
33 *Reumatologia Clinica*. 2016; 12(6):327-330
- 34 185. Vazquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health  
35 outcomes of children with facial nerve palsy attributable to Lyme disease. *Pediatrics*.  
36 2003; 112(2):e93-97
- 37 186. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme  
38 borreliosis. *Journal of Infection*. 1994; 29(3):255-261
- 39 187. Weber K, Neubert U, Thurmayer R. Antibiotic therapy in early erythema migrans  
40 disease and related disorders. *Zentralblatt für Bakteriologie, Mikrobiologie, und*  
41 *Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology,*  
42 *Parasitology*. 1987; 263(3):377-388
- 43 188. Weber K, Preac-Mursic V, Neubert U, Thurmayer R, Herzer P, Wilske B et al.  
44 Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica  
45 atrophicans. *Annals of the New York Academy of Sciences*. 1988; 539:324-345

- 1 189. Weissenbacher S, Ring J, Hofmann H. Gabapentin for the symptomatic treatment of  
2 chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.  
3 *Dermatology*. 2005; 211(2):123-127
- 4 190. White B, Seaton RA, Evans TJ. Management of suspected lyme borreliosis:  
5 experience from an outpatient parenteral antibiotic therapy service. *QJM*. 2013;  
6 106(2):133-138
- 7 191. Zochling N, Mullegger RR, Schluepen EM, Soyer HP, Hodl S, Wienecke R et al.  
8 Minocycline in early Lyme Borreliosis. *Acta Dermatovenerologica Alpina, Panonica et*  
9 *Adriatica*. 1996; 5(3-4):163-168
- 10

# 1 Appendices

## 2 Appendix A: Review protocols

3 **Table 4: Review protocol for the management of non-neurological ocular**  
 4 **manifestations related to Lyme disease**

5 Question number: 4.8

6 Relevant section of Scope: management

Field	Content
Review question	What is the most clinically and cost-effective treatment for people with non-neurological ocular manifestations related to Lyme disease (for example, keratitis, uveitis, iritis, scleritis)?
Type of review question	Intervention  A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	The review questions on the condition-specific management of Lyme disease aim to identify the most effective treatment in different clinical scenarios. The questions have been developed in a way to identify the evidence for all potential populations and scenarios, even if clinical presentations are more diverse. The population for this review consists of people with non-neurological ocular manifestations related to Lyme disease.
Eligibility criteria – population / disease / condition	Adults (18 years and over), young people (12 to 17 years) and children (under 12 years) with symptoms consistent with non-neurological ocular manifestations related to Lyme disease: <ul style="list-style-type: none"> <li>• keratitis</li> <li>• uveitis</li> <li>• iritis</li> <li>• scleritis</li> </ul>
Eligibility criteria – intervention(s)	Antimicrobials, including but not limited to: <ul style="list-style-type: none"> <li>• Penicillins               <ul style="list-style-type: none"> <li>○ Amoxicillin (oral, IV)</li> <li>○ Ampicillin (oral, IV)</li> <li>○ Benzylpenicillin sodium / Penicillin G (IV)</li> <li>○ Including Augmentin (Amoxicillin and clavulanic acid; oral, IV)</li> <li>○ Phenoxyethylpenicillin / Penicillin V (oral)</li> </ul> </li> <li>• Tetracyclines               <ul style="list-style-type: none"> <li>○ Doxycycline (oral)</li> <li>○ Minocycline (oral)</li> </ul> </li> <li>• Cephalosporins               <ul style="list-style-type: none"> <li>○ Cefotaxime (IV)</li> <li>○ Ceftriaxone (IV)</li> <li>○ Cefuroxime axetil (oral)</li> </ul> </li> <li>• Macrolides               <ul style="list-style-type: none"> <li>○ Azithromycin (oral)</li> <li>○ Clarithromycin (oral, IV)</li> </ul> </li> <li>• Fluoroquinolones               <ul style="list-style-type: none"> <li>○ Ciprofloxacin (oral, IV)</li> </ul> </li> </ul>

Field	Content
	<ul style="list-style-type: none"> <li>○ Levofloxacin (oral, IV)</li> <li>○ Moxifloxacin (oral, IV)</li> <li>○ Nalidixic acid (oral)</li> <li>○ Norfloxacin (oral)</li> <li>○ Ofloxacin (oral, IV)</li> <li>○ Rifampicin (oral, IV)</li> </ul> <p>Steroids (corticosteroids)</p> <p>Non-steroidal anti-inflammatory drugs (NSAIDs)</p> <p>Mydriatics</p> <ul style="list-style-type: none"> <li>● Acetylcholine</li> <li>● Phenylephrine</li> </ul>
Eligibility criteria – comparator(s)	<ul style="list-style-type: none"> <li>● Any type of intervention compared to each other <ul style="list-style-type: none"> <li>○ If data are available, consider: <ul style="list-style-type: none"> <li>- Type of agent (within class or between class)</li> <li>- Route of administration</li> <li>- Duration of treatment: 1 month versus longer</li> </ul> </li> </ul> </li> <li>● Monotherapy versus polytherapy (any combination)</li> <li>● Antimicrobial treatment, steroids, NSAIDs or mydriatics compared to no treatment / placebo</li> </ul>
Outcomes and prioritisation	<p><b>Critical:</b></p> <ol style="list-style-type: none"> <li>1. Quality of life (any validated measure)</li> <li>2. Cure (resolution of non-neurological ocular symptoms)</li> <li>3. Reduction of non-neurological ocular symptoms</li> <li>4. Relapse of non-neurological ocular symptoms</li> </ol> <p><b>Important:</b></p> <ol style="list-style-type: none"> <li>5. Adverse events</li> </ol>
Eligibility criteria – study design	<p>RCTs</p> <p>Cohort studies (if no RCT evidence is found)</p>
Other inclusion exclusion criteria	<p>Date limits for search: none</p> <p>Language: English only</p> <p>Setting: all settings in which NHS care is provided or commissioned</p> <p>The following interventions will not be considered for inclusion:</p> <ul style="list-style-type: none"> <li>● Metronidazole</li> <li>● Trimethoprim</li> </ul>
Proposed sensitivity / subgroup analysis, or meta-regression	<p>The following groups will be considered separately if data are available (strata):</p> <ul style="list-style-type: none"> <li>● Children (under 12 years); young people and adults (12 years and over)</li> <li>● Onset of specific symptoms less than 6 weeks; 6 weeks to 6 months; over 6 months</li> </ul> <p>Subgroups (to be investigated if heterogeneity is identified):</p> <ul style="list-style-type: none"> <li>● Pregnant women</li> <li>● People who are immunocompromised</li> <li>● People in whom any previous course of treatment has failed</li> </ul>
Selection process – duplicate screening / selection / analysis	<p>Studies will be sifted by title and abstract. Potentially significant publications obtained in full text will then be assessed against the inclusion criteria specified in this protocol.</p>

Field	Content
Data management (software)	<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p> <p>GRADEpro will be used to assess the quality of evidence for each outcome</p> <p>Bibliographies, citations, study sifting and reference management will be managed using EndNote.</p> <p>Data extractions will be performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)</p>
Information sources – databases and dates	<p>Clinical searches  Medline, Embase, The Cochrane Library all years</p> <p>Health economic searches  Medline, Embase, NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) all years</p>
Identify if an update	Not applicable
Author contacts	<a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10007">https://www.nice.org.uk/guidance/indevelopment/gid-ng10007</a>
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for one database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	<p>Standard study checklists were used to appraise individual studies critically. For details, please see section 6.2 of Developing NICE guidelines: the manual</p> <p>The risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group  <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p>
Criteria for quantitative synthesis	<p>For details, please see section 6.4 of Developing NICE guidelines: the manual.</p> <p>Meta-analysis will be conducted wherever possible (that is, where similar studies can be combined)</p> <p>In the absence of clinically established MIDs, standard MIDs for dichotomous (25% risk reduction or risk increase) and continuous outcomes (+/-0.5 standard deviation) will be used</p> <p>If heterogeneity is found, the influence of subgroups will be examined</p>
Methods for quantitative analysis – combining studies and exploring (in)consistency	For details, please see the separate Methods report for this guideline.
Meta-bias assessment – publication bias, selective reporting bias	For details, please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details, please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of	A multidisciplinary committee developed the evidence review. The

Field	Content
authors and guarantor	committee was convened by the NGC and chaired by Saul Faust in line with section 3 of Developing NICE guidelines: the manual. Staff from the NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds the NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

1

**Table 5: Health economic review protocol**

Review question	All questions – health economic evidence
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2001, abstract-only studies and studies from non-OECD countries or the US will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>15</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both, then there is discretion over whether it should be included.</li> </ul> <p><b>Where there is discretion</b></p> <p>The health economist will make a decision based on the relative applicability and</p>

quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude the remaining studies selectively. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

*Setting:*

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.

*Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

*Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2001 or later but that depend on unit costs and resource data entirely or predominantly before 2001 will be rated as ‘Not applicable’.
- Studies published before 2001 will be excluded before being assessed for applicability and methodological limitations.

*Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.



## Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2017  
<https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869>

For more detailed information, please see the Methodology Review.

### B.1 Clinical search literature search strategy

The search for this review was constructed using population terms. An excluded studies filter was applied where appropriate.

**Table 6: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 03 July 2017	Exclusions
Embase (OVID)	1974 – 03 July 2017	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2017 Issue 7 of 12 CENTRAL to 2017 Issue 6 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4	None

#### Medline (Ovid) search terms

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20

22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language

1

### Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	(letter or comment*).ti.
16.	or/12-15
17.	randomized controlled trial/ or random*.ti,ab.
18.	16 not 17
19.	animal/ not human/
20.	Nonhuman/
21.	exp Animal Experiment/
22.	exp Experimental animal/
23.	Animal model/
24.	exp Rodent/
25.	(rat or rats or mouse or mice).ti.
26.	or/18-25
27.	11 not 26
28.	limit 27 to English language

2

### Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Borrelia Infections] explode all trees
#2.	MeSH descriptor: [Lyme Disease] explode all trees
#3.	MeSH descriptor: [Erythema Chronicum Migrans] explode all trees
#4.	(erythema near/3 migrans):ti,ab

#5.	lyme*:ti,ab
#6.	(tick* near/2 (bite* or bitten or biting or borne)):ti,ab
#7.	acrodermatitis chronica atrophicans:ti,ab
#8.	MeSH descriptor: [Ixodidae] explode all trees
#9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or ixodid or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti):ti,ab
#10.	(granulocytic anaplasmosis or babesia or babesiosis):ti,ab
#11.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10

## 1 B.2 Health Economics literature search strategy

2 Health economic evidence was identified by conducting a broad search relating to Lyme  
 3 disease population in NHS Economic Evaluation Database (NHS EED – this ceased to be  
 4 updated after March 2015) and the Health Technology Assessment database (HTA) with no  
 5 date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and  
 6 Dissemination (CRD). Additional searches were run on Medline and Embase for health  
 7 economics, economic modelling and quality of life studies.

8 **Table 7: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	1974 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 03 July 2017 NHSEED - Inception to March 2015	None

## 9 **Medline (Ovid) search terms**

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/

13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20
22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language
31.	Economics/
32.	Value of life/
33.	exp "Costs and Cost Analysis"/
34.	exp Economics, Hospital/
35.	exp Economics, Medical/
36.	Economics, Nursing/
37.	Economics, Pharmaceutical/
38.	exp "Fees and Charges"/
39.	exp Budgets/
40.	budget*.ti,ab.
41.	cost*.ti.
42.	(economic* or pharmaco?economic*).ti.
43.	(price* or pricing*).ti,ab.
44.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
45.	(financ* or fee or fees).ti,ab.
46.	(value adj2 (money or monetary)).ti,ab.
47.	or/31-46
48.	exp models, economic/
49.	*Models, Theoretical/
50.	*Models, Organizational/
51.	markov chains/
52.	monte carlo method/

53.	exp Decision Theory/
54.	(markov* or monte carlo).ti,ab.
55.	econom* model*.ti,ab.
56.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
57.	or/48-56
58.	quality-adjusted life years/
59.	sickness impact profile/
60.	(quality adj2 (wellbeing or well being)).ti,ab.
61.	sickness impact profile.ti,ab.
62.	disability adjusted life.ti,ab.
63.	(qal* or qtime* or qwb* or daly*).ti,ab.
64.	(euroqol* or eq5d* or eq 5*).ti,ab.
65.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
66.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
67.	(hui or hui1 or hui2 or hui3).ti,ab.
68.	(health* year* equivalent* or hye or hyes).ti,ab.
69.	discrete choice*.ti,ab.
70.	rosser.ti,ab.
71.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
72.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
73.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
74.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
75.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
76.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
77.	or/58-76
78.	30 and 47
79.	30 and 57
80.	30 and 77

1

### Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.

11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	Case report/ or Case study/
16.	(letter or comment*).ti.
17.	or/12-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animal/ not human/
21.	Nonhuman/
22.	exp Animal Experiment/
23.	exp Experimental animal/
24.	Animal model/
25.	exp Rodent/
26.	(rat or rats or mouse or mice).ti.
27.	or/19-26
28.	11 not 27
29.	limit 28 to English language
30.	health economics/
31.	exp economic evaluation/
32.	exp health care cost/
33.	exp fee/
34.	budget/
35.	funding/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/30-42
44.	statistical model/
45.	exp economic aspect/
46.	44 and 45
47.	*theoretical model/
48.	*nonbiological model/
49.	stochastic model/
50.	decision theory/

51.	decision tree/
52.	monte carlo method/
53.	(markov* or monte carlo).ti,ab.
54.	econom* model*.ti,ab.
55.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
56.	or/46-55
57.	quality adjusted life year/
58.	"quality of life index"/
59.	short form 12/ or short form 20/ or short form 36/ or short form 8/
60.	sickness impact profile/
61.	(quality adj2 (wellbeing or well being)).ti,ab.
62.	sickness impact profile.ti,ab.
63.	disability adjusted life.ti,ab.
64.	(qal* or qtime* or qwb* or daly*).ti,ab.
65.	(euroqol* or eq5d* or eq 5*).ti,ab.
66.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
67.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
68.	(hui or hui1 or hui2 or hui3).ti,ab.
69.	(health* year* equivalent* or hye or hyes).ti,ab.
70.	discrete choice*.ti,ab.
71.	rosser.ti,ab.
72.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
73.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
74.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
75.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
76.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
77.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
78.	or/57-77
79.	29 and 43
80.	29 and 56
81.	29 and 78

1

### NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Borrelia Infections EXPLODE ALL TREES IN NHSEED,HTA
#2.	MeSH DESCRIPTOR Erythema Chronicum Migrans EXPLODE ALL TREES IN NHSEED,HTA
#3.	((erythema adj3 migrans)) IN NHSEED, HTA
#4.	(lyme*) IN NHSEED, HTA
#5.	((tick* adj2 (bite* or bitten or biting or borne))) IN NHSEED, HTA
#6.	(acrodermatitis chronica atrophicans) IN NHSEED, HTA
#7.	MeSH DESCRIPTOR Ixodidae EXPLODE ALL TREES IN NHSEED,HTA
#8.	((borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti)) IN NHSEED, HTA
#9.	((granulocytic anaplasmosis or babesia or babesiosis)) IN NHSEED, HTA
#10.	MeSH DESCRIPTOR Lyme Disease EXPLODE ALL TREES IN NHSEED,HTA

#11.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
------	---


1



1

## Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the reviews of the management of specific clinical scenarios for Lyme disease



2

## Appendix D: Clinical evidence tables

None.

1 **Appendix E: Forest plots**

2 None.


## Appendix F: GRADE tables

None.

1  
2

# Appendix G: Health economic evidence selection

Figure 2: Flow chart of economic study selection for the guideline



\* Non-relevant population, intervention, comparison, design or setting; non-English language

3

## Appendix H: Health economic evidence tables

None.

# Appendix I: Excluded studies

## I.1 Excluded clinical studies

**Table 8: Studies excluded from the clinical management reviews**

Reference	Reason for exclusion
Aberer 2006 <sup>1</sup>	Excluded due to an incorrect intervention
Abrutyn 1989 <sup>2</sup>	Excluded due to an incorrect study design
Agger 1992 <sup>3</sup>	Excluded due to an incorrect study design
Agus 1995 <sup>4</sup>	Excluded due to an incorrect study design
Agwuh 2006 <sup>5</sup>	Excluded due to an incorrect study design
Ahmed 2005 <sup>6</sup>	Excluded due to an incorrect study design
Ahmed 2013 <sup>7</sup>	Excluded due to an incorrect study design
Alarcon 1994 <sup>8</sup>	Excluded due to an incorrect study design
Andiman 1986 <sup>9</sup>	Excluded due to an incorrect study design
Anonymous 1991 <sup>10</sup>	Excluded due to an incorrect study design
Arvikar 2015 <sup>11</sup>	Excluded due to an incorrect study design
Auwaerter 2004 <sup>12</sup>	Excluded due to an incorrect study design
Bennet 2003 <sup>13</sup>	Excluded due to an incorrect study design
Berende 2014 <sup>14</sup>	Excluded due to an incorrect study design
Berger 1988 <sup>16</sup>	Excluded due to an incorrect study design
Berger 1986 <sup>15</sup>	Excluded due to an incorrect study design
Bernardino 2009 <sup>17</sup>	Excluded due to an incorrect study design
Bhate 2011 <sup>18</sup>	Excluded due to an incorrect study design
Bjark 2016 <sup>19</sup>	Not available
Borg 2005 <sup>22</sup>	Excluded due to an incorrect study design
Bratton 2008 <sup>23</sup>	Excluded due to an incorrect study design
Bremell 2014 <sup>24</sup>	Excluded due to an incorrect study design
British Infection Association 2011 <sup>25</sup>	Excluded due to an incorrect study design
Butler 1978 <sup>26</sup>	Excluded due to an incorrect population
Cadavid 2016 <sup>27</sup>	Excluded due to an incorrect study design
Canadian Paediatric Society 1992 <sup>28</sup>	Excluded due to an incorrect study design
Chen 1999 <sup>30</sup>	Excluded due to an incorrect outcome
Choo-Kang 2010 <sup>31</sup>	Excluded due to an incorrect study design
Christian 1992 <sup>32</sup>	Excluded due to an incorrect study design
Cimmino 1992 <sup>34</sup>	Excluded due to an incorrect study design
Cimmino 1997 <sup>33</sup>	Excluded due to an incorrect study design
Cimperman 1999 <sup>35</sup>	Excluded due to an incorrect study design
Coblyn 1981 <sup>36</sup>	Excluded due to an incorrect study design
Committee on Infectious Diseases 1991 <sup>38</sup>	Excluded due to an incorrect study design
Cuisset 2008 <sup>39</sup>	Excluded due to an incorrect study design
Dattwyler 1996 <sup>41</sup>	Excluded due to an incorrect comparison
Dattwyler 1987 <sup>42</sup>	Excluded due to an incorrect study design
Dattwyler 1988 <sup>43</sup>	Excluded due to an incorrect population
Dattwyler 2005 <sup>44</sup>	Excluded due to an incorrect population

Reference	Reason for exclusion
Dersch 2015 <sup>46</sup>	Excluded due to an incorrect study design
Dersch 2016 <sup>49</sup>	Excluded due to an incorrect study design
Dersch 2014 <sup>47</sup>	Excluded due to an incorrect study design
Dersch 2017 <sup>48</sup>	Not available
Dhoot 2011 <sup>50</sup>	Excluded due to an incorrect study design
Dinser 2005 <sup>51</sup>	Excluded due to an incorrect study design
Dotevall 1988 <sup>52</sup>	Excluded due to an incorrect study design
Eliassen 2017 <sup>53</sup>	Excluded due to an incorrect study design
Eliassen 2017 <sup>54</sup>	Excluded due to an incorrect intervention
Eppes 2003 <sup>55</sup>	Excluded due to an incorrect study design
Esposito 2013 <sup>56</sup>	Excluded due to an incorrect study design
Fallon 1999 <sup>58</sup>	Excluded due to an incorrect intervention
Fallon 2008 <sup>57</sup>	Excluded due to an incorrect outcome
Galev 2005 <sup>59</sup>	Excluded due to an incorrect study design
Garkowski 2017 <sup>60</sup>	Systematic review
Gasser 1996 <sup>62</sup>	Excluded due to an incorrect not available
Gasser 1995 <sup>63</sup>	Excluded due to an incorrect study design
Gasser 1995 <sup>61</sup>	Excluded due to an incorrect study design
Gerber 1996 <sup>64</sup>	Excluded due to an incorrect intervention
Gillies 2015 <sup>65</sup>	Excluded due to an incorrect study design
Goodwin 1990 <sup>66</sup>	Excluded due to an incorrect study design
Hansen 1992 <sup>67</sup>	Excluded due to an incorrect intervention
Hassler 1990 <sup>68</sup>	Excluded due to an incorrect population
Horton 2017 <sup>69</sup>	Conference abstract
Hu 2001 <sup>70</sup>	Excluded due to an incorrect study design
Inboriboon 2010 <sup>71</sup>	Excluded due to an incorrect study design
Kaplan 2003 <sup>72</sup>	Excluded due to an incorrect population
Karkkonen 2001 <sup>73</sup>	Excluded due to an incorrect study design
Karlsson 1996 <sup>74</sup>	Excluded due to an incorrect outcome
Kersten 1995 <sup>75</sup>	Excluded due to an incorrect study design
Kilic Muftuoglu 2016 <sup>76</sup>	Excluded due to an incorrect study design
Klempner 2013 <sup>78</sup>	Excluded due to an incorrect study design
Korenberg 1996 <sup>79</sup>	Excluded due to an incorrect intervention
Kowalski 2010 <sup>81</sup>	Excluded due to an incorrect outcome
Kowalski 2011 <sup>80</sup>	Excluded due to an incorrect study design
Krbkova 1996 <sup>82</sup>	Excluded due to an incorrect comparison
Kuhn 2012 <sup>83</sup>	Excluded due to an incorrect study design
Laasila 2003 <sup>84</sup>	Excluded due to an incorrect population
Lantos 2013 <sup>85</sup>	Excluded due to an incorrect study design
Lauhio 1994 <sup>86</sup>	Excluded due to an incorrect population
Lauhio 1991 <sup>87</sup>	Excluded due to an incorrect population
Lempner 2002 <sup>77</sup>	Excluded due to an incorrect study design
Liegner 1992 <sup>88</sup>	Excluded due to an incorrect study design
Lipsker 2002 <sup>89</sup>	Excluded due to an incorrect study design
Ljostad 2008 <sup>90</sup>	Study abstract



Reference	Reason for exclusion
Loewen 1999 <sup>91</sup>	Excluded due to an incorrect study design
Loewen 2000 <sup>92</sup>	Excluded due to an incorrect study design
Luft 1988 <sup>94</sup>	Excluded due to an incorrect outcome
Luft 1989 <sup>93</sup>	Excluded due to an incorrect population
Maraspin 1995 <sup>100</sup>	Excluded due to an incorrect study design
Maraspin 1996 <sup>95</sup>	Excluded due to an incorrect study design
Maraspin 1999 <sup>96</sup>	Excluded due to an incorrect study design
Maraspin 2002 <sup>97</sup>	Excluded due to an incorrect study design
Maraspin 1999 <sup>98</sup>	Excluded due to an incorrect study design
Maraspin 2002 <sup>99</sup>	Excluded due to an incorrect population
Marks 2016 <sup>101</sup>	Excluded due to an incorrect study design
McGill 1965 <sup>102</sup>	Excluded due to an incorrect population
Meyerhoff 2002 <sup>103</sup>	Excluded due to an incorrect study design
Meyerhoff 2016 <sup>104</sup>	Excluded due to an incorrect study design
Millner 1996 <sup>105</sup>	Excluded due to an incorrect outcome
Millner 1996 <sup>106</sup>	Excluded due to an incorrect outcome
Morales 2000 <sup>107</sup>	Excluded due to an incorrect study design
Muellegger 1995 <sup>109</sup>	Excluded due to an incorrect study design
Muellegger 1996 <sup>108</sup>	Excluded due to an incorrect comparison
Mullegger 1991 <sup>110</sup>	Excluded due to an incorrect outcome
Nadelman 1993 <sup>112</sup>	Excluded due to an incorrect study design
Nadelman 2001 <sup>111</sup>	Excluded due to an incorrect population
Naglo 1989 <sup>113</sup>	Excluded due to an incorrect study design
Neumann 1987 <sup>116</sup>	Excluded due to an incorrect study design
Nimmrich 2014 <sup>118</sup>	Excluded due to an incorrect study design
Nowakowski 2000 <sup>119</sup>	Excluded due to an incorrect study design
Nowakowski 1995 <sup>120</sup>	Excluded due to an incorrect study design
Ogrinc 2006 <sup>121</sup>	Excluded due to an incorrect population
Oksi 1999 <sup>122</sup>	Excluded due to an incorrect study design
Oksi 2007 <sup>123</sup>	Excluded due to an incorrect population
Oksi 1998 <sup>124</sup>	Excluded due to an incorrect population
Peltomaa 1998 <sup>125</sup>	Excluded due to an incorrect comparison
Pena 1999 <sup>126</sup>	Excluded due to an incorrect study design
Perronne 2015 <sup>127</sup>	Not available
Pfister 1988 <sup>128</sup>	Excluded due to an incorrect outcome
Pirila 1951 <sup>131</sup>	Excluded due to an incorrect study design
Plorer 1993 <sup>132</sup>	Excluded due to an incorrect study design
Plotkin 1991 <sup>133</sup>	Excluded due to an incorrect study design
Puchalska 1996 <sup>134</sup>	Excluded due to an incorrect study design
Puri 2015 <sup>135</sup>	Excluded due to an incorrect comparison
Puri 2015 <sup>136</sup>	Excluded due to an incorrect study design
Rebman 2015 <sup>137</sup>	Excluded due to an incorrect study design
Renaud 2004 <sup>138</sup>	Excluded due to an incorrect study design
Rohacova 1996 <sup>139</sup>	Excluded due to an incorrect comparison
Rose 1994 <sup>140</sup>	Excluded due to an incorrect study design

Reference	Reason for exclusion
Rose 1996 <sup>141</sup>	Excluded due to an incorrect intervention
Rubin 1992 <sup>142</sup>	Excluded due to an incorrect study design
Salazar 2005 <sup>143</sup>	Excluded due to an incorrect intervention
Salazar 1993 <sup>144</sup>	Excluded due to an incorrect study design
Sanchez 2016 <sup>145</sup>	Excluded due to an incorrect study design
Sandstrom 1989 <sup>146</sup>	Excluded due to an incorrect study design
Schmidt 1995 <sup>147</sup>	Excluded due to an incorrect study design
Selby 2008 <sup>148</sup>	Excluded due to an incorrect study design
Shadick 1994 <sup>149</sup>	Excluded due to an incorrect study design
Shadick 1999 <sup>150</sup>	Excluded due to an incorrect study design
Shemanski 2016 <sup>151</sup>	Excluded due to an incorrect study design
Shoemaker 2006 <sup>152</sup>	Excluded due to an incorrect intervention
Sjowall 2012 <sup>154</sup>	Excluded due to an incorrect intervention
Sjowall 2011 <sup>153</sup>	Excluded due to an incorrect study design
Skogman 2003 <sup>156</sup>	Excluded due to an incorrect intervention
Skogman 2008 <sup>155</sup>	Excluded due to an incorrect study design
Skoldenberg 1988 <sup>157</sup>	Excluded due to an incorrect study design
Smith 2002 <sup>158</sup>	Excluded due to an incorrect study design
Solomon 1998 <sup>159</sup>	Excluded due to an incorrect intervention
Spathling 1992 <sup>160</sup>	Article not in English
Stanek 1999 <sup>161</sup>	Excluded due to an incorrect study design
Steere 1980 <sup>165</sup>	Excluded due to an incorrect study design
Steere 1983 <sup>166</sup>	Excluded due to an incorrect study design
Steere 1987 <sup>162</sup>	Excluded due to an incorrect study design
Steurer 2016 <sup>167</sup>	Article not in English
Stricker 2011 <sup>168</sup>	Excluded due to an incorrect study design
Stricker 2010 <sup>169</sup>	Excluded due to an incorrect study design
Strle 1996 <sup>170</sup>	Excluded due to an incorrect outcome
Strle 1996 <sup>171</sup>	Excluded due to an incorrect outcome
Strle 1992 <sup>172</sup>	Excluded due to an incorrect study design
Strle 1993 <sup>173</sup>	Excluded due to an incorrect outcome
Stupica 2015 <sup>175</sup>	Excluded due to an incorrect comparison
Stupica 2011 <sup>174</sup>	Excluded due to an incorrect comparison
Suarez-Magdalena 2017 <sup>176</sup>	Not available
Thompson 2012 <sup>177</sup>	Excluded due to an incorrect study design
Thorstrand 2002 <sup>178</sup>	Excluded due to an incorrect study design
Thyresson 1949 <sup>179</sup>	Excluded due to an incorrect study design
Torbahn 2016 <sup>180</sup>	Excluded due to an incorrect study design
Tory 2010 <sup>181</sup>	Excluded due to an incorrect comparison
Tseng 2017 <sup>182</sup>	Excluded due to an incorrect outcome
Valesova 1996 <sup>183</sup>	Excluded due to an incorrect comparison
Vazquez 2003 <sup>185</sup>	Excluded due to an incorrect study design
Vazquez-Lopez 2016 <sup>184</sup>	Excluded due to an incorrect study design
Wahlberg 1994 <sup>186</sup>	Excluded due to an incorrect intervention
Weber 1988 <sup>188</sup>	Excluded due to an incorrect study design

Reference	Reason for exclusion
Weber 1987 <sup>187</sup>	Excluded due to an incorrect population
Weissenbacher 2005 <sup>189</sup>	Excluded due to an incorrect intervention
White 2013 <sup>190</sup>	Excluded due to an incorrect study design
Zochling 1996 <sup>191</sup>	Excluded due to an incorrect study design

## 1 I.2 Excluded health economic studies

2 Table 9: Studies excluded from the health economic review

Reference	Reason for exclusion
None	None

3